Christopher Sweeney, MBBS, on Treating Prostate Cancer With PI3K/AKT Pathway Alterations

Posted: Wednesday, February 17, 2021

Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, discusses the challenges of treating patients with metastatic castration-resistant prostate cancer and PI3K/AKT pathway alterations, a subtype with a poor prognosis. The combination of ipatasertib and abiraterone has been shown to be effective, and biomarkers may provide clues about what to expect in terms of responsiveness.